A retrospective study across five U.S. pediatric hospitals found that over half of pediatric and adolescent patients treated with fidaxomicin for Clostridioides difficile infections were clinically cured within 2 weeks, with fewer than one-quarter experiencing recurrence by day 60. The study included 95 patients aged 12 months to 18 years who were treated for primary or recurrent CDI, and most had underlying medical or surgical conditions. Fidaxomicin showed promise as a viable treatment option, especially for patients with recurrent or refractory disease.

Source: The Journal of Pediatrics